Daily Signals
2696 companies scored · 2026-10-15 run in progress: 5121 of ~5380 signals so far · Alpha · vs marketSwitch to Total · 30D 90D
Distribution of the day's forecasts
30D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
304 companies
Sorted by market cap ↓ · forecast rankings are part of the paid plans
| Ticker | Rating | 30D | Δ | |
|---|---|---|---|---|
| LLYELI LILLY & Co | -0.25% | ▲ 1 | ||
| JNJJOHNSON & JOHNSON | Unlock rating and forecasts | |||
| ABBVAbbVie Inc. | -0.25% | ▲ 1 | ||
| MRKMerck & Co., Inc. | -0.11% | · | ||
| AZNASTRAZENECA PLC | Unlock rating and forecasts | |||
| AMGNAMGEN INC | Unlock rating and forecasts | |||
| GILDGILEAD SCIENCES, INC. | Unlock rating and forecasts | |||
| ABTABBOTT LABORATORIES | Unlock rating and forecasts | |||
| NVONOVO NORDISK A S | Unlock rating and forecasts | |||
| PFEPFIZER INC | Unlock rating and forecasts | |||
| BMYBRISTOL MYERS SQUIBB CO | -0.26% | · | ||
| SNYSanofi | Unlock rating and forecasts | |||
| GSKGSK plc | Unlock rating and forecasts | |||
| MRNAModerna, Inc. | Unlock rating and forecasts | |||
| REGNREGENERON PHARMACEUTICALS, INC. | -0.29% | ▼ 1 | ||
| ARGXARGENX SE | Unlock rating and forecasts | |||
| IDXXIDEXX LABORATORIES INC /DE | Unlock rating and forecasts | |||
| RVMDRevolution Medicines, Inc. | Unlock rating and forecasts | |||
| ONCBeOne Medicines Ltd. | Unlock rating and forecasts | |||
| BIIBBIOGEN INC. | Unlock rating and forecasts | |||
| RPRXRoyalty Pharma plc | +0.15% | · | ||
| ALNYALNYLAM PHARMACEUTICALS, INC. | +0.05% | ▼ 1 | ||
| ZTSZoetis Inc. | -0.20% | ▲ 1 | ||
| ZLABZai Lab Ltd | Unlock rating and forecasts | |||
| ROIVRoivant Sciences Ltd. | Unlock rating and forecasts | |||
| GMABGENMAB A/S | +0.07% | ▼ 2 | ||
| UTHRUNITED THERAPEUTICS Corp | -0.06% | · | ||
| BNTXBioNTech SE | Unlock rating and forecasts | |||
| INSMINSMED Inc | 0.00% | · | ||
| VTRSViatris Inc | -0.09% | · | ||
| ASNDAscendis Pharma A/S | Unlock rating and forecasts | |||
| NBIXNEUROCRINE BIOSCIENCES INC | Unlock rating and forecasts | |||
| JAZZJazz Pharmaceuticals plc | Unlock rating and forecasts | |||
| HALOHALOZYME THERAPEUTICS, INC. | +0.09% | ▼ 1 | ||
| BBIOBridgeBio Pharma, Inc. | -0.04% | ▼ 1 | ||
| CORTCORCEPT THERAPEUTICS INC | Unlock rating and forecasts | |||
| SMMTSummit Therapeutics Inc. | +0.04% | · | ||
| TECHBIO-TECHNE Corp | Unlock rating and forecasts | |||
| ELANElanco Animal Health Inc | Unlock rating and forecasts | |||
| BMRNBIOMARIN PHARMACEUTICAL INC | -0.24% | · | ||
| IBRXImmunityBio, Inc. | Unlock rating and forecasts | |||
| RGENREPLIGEN CORP | -0.01% | ▼ 1 | ||
| QGENQIAGEN N.V. | -0.05% | · | ||
| KRYSKrystal Biotech, Inc. | -0.28% | · | ||
| TWSTTwist Bioscience Corp | Unlock rating and forecasts | |||
| CYTKCYTOKINETICS INC | Unlock rating and forecasts | |||
| AXSMAxsome Therapeutics, Inc. | Unlock rating and forecasts | |||
| ARWRARROWHEAD PHARMACEUTICALS, INC. | Unlock rating and forecasts | |||
| IONSIONIS PHARMACEUTICALS INC | Unlock rating and forecasts | |||
| SYRESpyre Therapeutics, Inc. | Unlock rating and forecasts | |||
By sector
Median 30D forecast per sector. Click to filter.
Rating changes
Unlock the full ranking
Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.
See plans Create a free accountRatings are relative: the forecasts of the latest complete daily run (2026-10-15) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.